Michael R Brandt

7098200, Aug 29, 2006

Oct 9, 2002

10/267159

Michael Richard Brandt - Flemington NJ, US
Margaret Maria Zaleska - Narberth PA, US
John Allen Moyer - New Hope PA, US

Wyeth - Madison NJ

A01N 43/00
A01N 43/58
A01N 43/50
A61K 31/33
A61K 31/55

514183, 514221, 514249

This invention provides a method of treating pain in a mammal that includes administering to a mammal in need of such treatment a pain treating effective amount of a compound of the formula (I):.

7759346, Jul 20, 2010

May 12, 2006

11/433737

Michael Richard Brandt - Flemington NJ, US
Margaret Maria Zaleska - Narberth PA, US
John Allen Moyer - New Hope PA, US

Wyeth LLC - Madison NJ

A01N 57/00
A01N 43/62
A61K 31/69
C07D 243/12

514249, 514 75, 514221, 540517

This invention provides a method of treating pain in a mammal that includes administering to a mammal in need of such treatment a pain treating effective amount of a compound of the formula (I):.

7951829, May 31, 2011

Apr 13, 2007

11/734984

Mark R. Player - Phoenixville PA, US
Scott L. Dax - Landenberg PA, US
William H. Parsons - Belle Mead NJ, US
Michael Richard Brandt - Flemington NJ, US
Raul R. Calvo - Royerford PA, US
Sharmila Patel - Jamison PA, US
Jian Liu - Manalapan NJ, US
Wing S. Cheung - Plainsboro NJ, US
Michele C. Jetter - Norristown PA, US
Yu-Kai Lee - Exton PA, US
Mark A. Youngman - Warminster PA, US
Wenxi Pan - Glenmore PA, US
Kenneth M. Wells - Hillsborough NJ, US
Derek A. Beauchamp - Watchung NJ, US

Janssen Pharmaceutica NV

A01N 43/52
C07D 235/00

514394, 5483044

The invention is directed to compounds of Formula (I):.

20030024001, Jan 30, 2003

Jul 16, 2002

10/196890

Seung Kwak - Princeton NJ, US
Kenneth Rhodes - Hillsborough NJ, US
Karen Marquis - Yardley PA, US
Thomas Comery - Langhorne PA, US
Roger Askew - Boxford MA, US
Michael Brandt - Flemington NJ, US

Wyeth - Madison NJ

A01K067/027

800/018000, 800/014000

This invention provides a transgenic mammal containing a defective beta 1 subunit (Kv1) of a voltage sensitive potassium channel, where the Kv1 subunit is unable to confer N-type inactivation of the K but retains the ability to co-associate with Kv1 family -subunits and thereby enhance channel surface expression. Preferably the Kv1.1 gene encoding Kv1 subunit has a mutation in all or a portion of codons 1-70 of its inactivation domain. The transgenic mammal is useful as a model for psychiatric and neurological disorders to identify anxiolytic compounds and pro-cognitive functions. The invention also provides for methods for screening and evaluating test compounds for their ability to modulate Kv1.1 activity, specifically for inactivation of a potassium channel or for co-association with -subunits.

20050004079, Jan 6, 2005

Apr 7, 2004

10/820215

Eric Benjamin - Jamestown NC, US
Reinhardt Baudy - Buckingham PA, US
Michael Brandt - Flemington NJ, US

Wyeth - Madison NJ

A61K031/675

514080000

Pharmaceutical compositions for intranasal administration are provided that contain at least one compound of formula (I) or a pharmaceutically acceptable salt thereof: and one or more pharmaceutically acceptable additives for forming a composition for intranasal administration. Also provided are methods of treating one or more conditions in a mammal associated with a glutamate abnormality that includes administering intranasally to a mammal a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

20050142192, Jun 30, 2005

Oct 8, 2004

10/961871

Eric Benjamin - Jamestown NC, US
William Cloud - Garnerville NY, US
Muhammad Ashraf - Elmwood Park NJ, US
Mohammed Islam - Harriman NY, US
Michael Brandt - Flemington NJ, US
Gerald Tremblay - Lansdale PA, US

Wyeth - Madison NJ

A61K031/675
A61K009/20

424464000, 514080000

Solid, pharmaceutical dosage forms of [2-(8,9-dioxo-2,6-diazabicyclo [5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic acid and derivatives thereof are disclosed. In addition, methods of use are disclosed for the treatment, inter alia, of cerebral vascular disorders, anxiety disorders; mood disorders; schizophrenia; schizophreniform disorder; schizoaffective disorder; cognitive impairment; chronic neurodegenerative disorders; inflammatory diseases; fibromyalgia; complications from herpes zoster; prevention of tolerance to opiate analgesia; withdrawal symptoms from addictive drugs; and pain.

20060258713, Nov 16, 2006

Apr 21, 2006

11/408909

Michael Brandt - Flemington NJ, US

Wyeth - Madison NJ

A61K 31/4433
A61K 31/381
A61K 31/343

514337000, 514444000, 514469000

This invention provides a method of treating pain in a mammal that includes administering to a mammal in need of such treatment a pain treating effective amount of a compound of the formula I: or a pharmaceutically acceptable salt thereof, wherein each of R, R, R, n, y, and Ar is as defined and described herein. The present invention also provides pharmaceutical compositions for treating pain containing a pain treating effective amount of the compound of formula I.

20110190344, Aug 4, 2011

Apr 12, 2011

13/084705

Mark R. Player - Phoenixville PA, US
Scott L. Dax - Landenberg PA, US
William H. Parsons - Belle Mead NJ, US
Michael Richard Brandt - Flemington NJ, US
Raul R. Calvo - Royersford PA, US
Sharmila Patel - Jamison PA, US
Jian Liu - Manalapan NJ, US
Wing S. Cheung - Plainsboro NJ, US
Michele C. Jetter - Norristown PA, US
Yu-Kai Lee - Exton PA, US
Mark A. Youngman - Warminster PA, US
Wenxi Pan - Glenmoore PA, US
Kenneth M. Wells - Hillsborough NJ, US
Derek A. Beauchamp - Watchung NJ, US

A61K 31/4184
C07D 235/04
C07D 401/10
A61K 31/4709
A61P 25/00

514314, 5483044, 514394, 546152

The invention is directed to compounds of Formula (I):to pharmaceutical compositions containing such compounds and to methods of treatment using them.